Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease

NCT04174105 is registered in ClinicalTrials.gov with Astellas Gene Therapies as lead sponsor.

NCT NCT04174105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04174105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients With Late Onset Pompe Disease
Lead sponsor
Astellas Gene Therapies
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 27, 2020
Completion date
February 28, 2035
Enrollment
11 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pompe disease (late-onset)